Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations
ICD-10 F16.251 is a billable code used to indicate a diagnosis of hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations.
Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations is characterized by a compulsive pattern of hallucinogen use leading to significant impairment or distress. Individuals with this condition experience persistent hallucinations, delusions, and other psychotic symptoms directly attributable to the use of hallucinogenic substances such as LSD, psilocybin, or mescaline. The dependence manifests as a strong desire to consume hallucinogens, often resulting in tolerance and withdrawal symptoms when not using the substance. The psychotic disorder component indicates that the individual experiences hallucinations that can affect their perception of reality, leading to potential risks of harm to themselves or others. Treatment typically involves a combination of psychotherapy, medication management, and support groups, focusing on both the substance use disorder and the psychotic symptoms. Clinicians must carefully assess the severity of the dependence and the impact of the psychotic disorder on the patient's functioning to develop an effective treatment plan.
Comprehensive psychiatric evaluation, including history of substance use, mental status examination, and treatment plan.
Patients presenting with acute psychosis following hallucinogen use, chronic users seeking treatment for dependence.
Documenting the timeline of substance use and onset of psychotic symptoms is crucial for accurate coding.
Detailed substance use history, assessment of withdrawal symptoms, and treatment response.
Patients in detoxification programs or those undergoing rehabilitation for hallucinogen dependence.
Focus on the impact of hallucinogen use on overall health and co-occurring mental health disorders.
Used for follow-up visits in patients with hallucinogen dependence and psychotic symptoms.
Document the patient's history, mental status examination, and treatment plan.
Psychiatrists should ensure that the visit details reflect the complexity of managing both substance use and psychotic symptoms.
F16.251 specifies hallucinogen dependence with psychotic disorder and hallucinations, while F16.20 is used for hallucinogen use disorder without specifying the presence of psychotic symptoms.
